Abstract
Previous studies showed that the addition of anti-VEGF inhibitors to erlotinib prolonged progression-free survival (PFS) in EGFR mutated non-squamous non-small-cell lung cancer (Ns-NSCLC) patients (pts). The primary results of WJOG9717L study, open-label, randomized phase II trial comparing Osimertinib (Osi) plus bevacizumab (Bev) with Osi monotherapy for untreated pts with advanced EGFR mutated Ns-NSCLC, were reported at ESMO2021.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call